A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia

Keith Pratz, Michelle Rudek-Renaut, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret Showel, Douglas Gladstone, Mark J Levis, Hua Ling Tsai, Gary Rosner, Alice Chen, Scott H. Kaufmann, Judith Karp

Research output: Contribution to journalArticle

Abstract

Purpose: The PARP inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy using a previously described topotecan/carboplatin backbone. Experimental Design: Employing a 3+3 trial design, we administered escalating doses of veliparib combined with topotecan + carboplatin in relapsed or refractory acute leukemias, aggressive myeloproliferative neoplasms (MPN), and chronic myelomonocytic leukemia (CMML). Results: A total of 99 patients received veliparib 10-100 mg orally twice daily on days 1-8, 1-14, or 1-21 along with continuous infusion topotecan 1.0-1.2 mg/m2/d + carboplatin 120-150 mg/m2/d on days 3-7. The MTD was veliparib 80 mg twice daily for up to 21 days with topotecan 1.2 mg/m2/d + carboplatin 150 mg/m2/d. Mucositis was dose limiting and correlated with high veliparib concentrations. The response rate was 33% overall (33/99: 14 CR, 11 CRi, 8 PR) but was 64% (14/22) for patients with antecedent or associated aggressive MPNs or CMML. Leukemias with baseline DNA repair defects, as evidenced by impaired DNA damage-induced FANCD2 monoubiquitination, had improved survival [HR = 0.56 (95% confidence interval, 0.27-0.92)]. A single 80-mg dose of veliparib, as well as veliparib in combination with topotecan + carboplatin, induced DNA damage as manifested by histone H2AX phosphorylation in CD34+ leukemia cells, with greater phosphorylation in cells from responders. Conclusions: The veliparib/topotecan/carboplatin combination warrants further investigation, particularly in patients with aggressive MPNs, CMML, and MPN- or CMML-related acute leukemias.

LanguageEnglish (US)
Pages899-907
Number of pages9
JournalClinical Cancer Research
Volume23
Issue number4
DOIs
StatePublished - Feb 15 2017

Fingerprint

Leukemia, Myelomonocytic, Chronic
Topotecan
Carboplatin
Leukemia
Neoplasms
DNA Repair
DNA Damage
Phosphorylation
Topoisomerase I Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
veliparib
Mucositis
Histones
Research Design
Confidence Intervals
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia. / Pratz, Keith; Rudek-Renaut, Michelle; Gojo, Ivana; Litzow, Mark R.; McDevitt, Michael A.; Ji, Jiuping; Karnitz, Larry M.; Herman, James G.; Kinders, Robert J.; Smith, B Douglas; Gore, Steven D.; Carraway, Hetty E.; Showel, Margaret; Gladstone, Douglas; Levis, Mark J; Tsai, Hua Ling; Rosner, Gary; Chen, Alice; Kaufmann, Scott H.; Karp, Judith.

In: Clinical Cancer Research, Vol. 23, No. 4, 15.02.2017, p. 899-907.

Research output: Contribution to journalArticle

Pratz, Keith ; Rudek-Renaut, Michelle ; Gojo, Ivana ; Litzow, Mark R. ; McDevitt, Michael A. ; Ji, Jiuping ; Karnitz, Larry M. ; Herman, James G. ; Kinders, Robert J. ; Smith, B Douglas ; Gore, Steven D. ; Carraway, Hetty E. ; Showel, Margaret ; Gladstone, Douglas ; Levis, Mark J ; Tsai, Hua Ling ; Rosner, Gary ; Chen, Alice ; Kaufmann, Scott H. ; Karp, Judith. / A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 4. pp. 899-907.
@article{4c57f59b8cb24a758844142a666c5190,
title = "A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia",
abstract = "Purpose: The PARP inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy using a previously described topotecan/carboplatin backbone. Experimental Design: Employing a 3+3 trial design, we administered escalating doses of veliparib combined with topotecan + carboplatin in relapsed or refractory acute leukemias, aggressive myeloproliferative neoplasms (MPN), and chronic myelomonocytic leukemia (CMML). Results: A total of 99 patients received veliparib 10-100 mg orally twice daily on days 1-8, 1-14, or 1-21 along with continuous infusion topotecan 1.0-1.2 mg/m2/d + carboplatin 120-150 mg/m2/d on days 3-7. The MTD was veliparib 80 mg twice daily for up to 21 days with topotecan 1.2 mg/m2/d + carboplatin 150 mg/m2/d. Mucositis was dose limiting and correlated with high veliparib concentrations. The response rate was 33{\%} overall (33/99: 14 CR, 11 CRi, 8 PR) but was 64{\%} (14/22) for patients with antecedent or associated aggressive MPNs or CMML. Leukemias with baseline DNA repair defects, as evidenced by impaired DNA damage-induced FANCD2 monoubiquitination, had improved survival [HR = 0.56 (95{\%} confidence interval, 0.27-0.92)]. A single 80-mg dose of veliparib, as well as veliparib in combination with topotecan + carboplatin, induced DNA damage as manifested by histone H2AX phosphorylation in CD34+ leukemia cells, with greater phosphorylation in cells from responders. Conclusions: The veliparib/topotecan/carboplatin combination warrants further investigation, particularly in patients with aggressive MPNs, CMML, and MPN- or CMML-related acute leukemias.",
author = "Keith Pratz and Michelle Rudek-Renaut and Ivana Gojo and Litzow, {Mark R.} and McDevitt, {Michael A.} and Jiuping Ji and Karnitz, {Larry M.} and Herman, {James G.} and Kinders, {Robert J.} and Smith, {B Douglas} and Gore, {Steven D.} and Carraway, {Hetty E.} and Margaret Showel and Douglas Gladstone and Levis, {Mark J} and Tsai, {Hua Ling} and Gary Rosner and Alice Chen and Kaufmann, {Scott H.} and Judith Karp",
year = "2017",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-16-1274",
language = "English (US)",
volume = "23",
pages = "899--907",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia

AU - Pratz, Keith

AU - Rudek-Renaut, Michelle

AU - Gojo, Ivana

AU - Litzow, Mark R.

AU - McDevitt, Michael A.

AU - Ji, Jiuping

AU - Karnitz, Larry M.

AU - Herman, James G.

AU - Kinders, Robert J.

AU - Smith, B Douglas

AU - Gore, Steven D.

AU - Carraway, Hetty E.

AU - Showel, Margaret

AU - Gladstone, Douglas

AU - Levis, Mark J

AU - Tsai, Hua Ling

AU - Rosner, Gary

AU - Chen, Alice

AU - Kaufmann, Scott H.

AU - Karp, Judith

PY - 2017/2/15

Y1 - 2017/2/15

N2 - Purpose: The PARP inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy using a previously described topotecan/carboplatin backbone. Experimental Design: Employing a 3+3 trial design, we administered escalating doses of veliparib combined with topotecan + carboplatin in relapsed or refractory acute leukemias, aggressive myeloproliferative neoplasms (MPN), and chronic myelomonocytic leukemia (CMML). Results: A total of 99 patients received veliparib 10-100 mg orally twice daily on days 1-8, 1-14, or 1-21 along with continuous infusion topotecan 1.0-1.2 mg/m2/d + carboplatin 120-150 mg/m2/d on days 3-7. The MTD was veliparib 80 mg twice daily for up to 21 days with topotecan 1.2 mg/m2/d + carboplatin 150 mg/m2/d. Mucositis was dose limiting and correlated with high veliparib concentrations. The response rate was 33% overall (33/99: 14 CR, 11 CRi, 8 PR) but was 64% (14/22) for patients with antecedent or associated aggressive MPNs or CMML. Leukemias with baseline DNA repair defects, as evidenced by impaired DNA damage-induced FANCD2 monoubiquitination, had improved survival [HR = 0.56 (95% confidence interval, 0.27-0.92)]. A single 80-mg dose of veliparib, as well as veliparib in combination with topotecan + carboplatin, induced DNA damage as manifested by histone H2AX phosphorylation in CD34+ leukemia cells, with greater phosphorylation in cells from responders. Conclusions: The veliparib/topotecan/carboplatin combination warrants further investigation, particularly in patients with aggressive MPNs, CMML, and MPN- or CMML-related acute leukemias.

AB - Purpose: The PARP inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy using a previously described topotecan/carboplatin backbone. Experimental Design: Employing a 3+3 trial design, we administered escalating doses of veliparib combined with topotecan + carboplatin in relapsed or refractory acute leukemias, aggressive myeloproliferative neoplasms (MPN), and chronic myelomonocytic leukemia (CMML). Results: A total of 99 patients received veliparib 10-100 mg orally twice daily on days 1-8, 1-14, or 1-21 along with continuous infusion topotecan 1.0-1.2 mg/m2/d + carboplatin 120-150 mg/m2/d on days 3-7. The MTD was veliparib 80 mg twice daily for up to 21 days with topotecan 1.2 mg/m2/d + carboplatin 150 mg/m2/d. Mucositis was dose limiting and correlated with high veliparib concentrations. The response rate was 33% overall (33/99: 14 CR, 11 CRi, 8 PR) but was 64% (14/22) for patients with antecedent or associated aggressive MPNs or CMML. Leukemias with baseline DNA repair defects, as evidenced by impaired DNA damage-induced FANCD2 monoubiquitination, had improved survival [HR = 0.56 (95% confidence interval, 0.27-0.92)]. A single 80-mg dose of veliparib, as well as veliparib in combination with topotecan + carboplatin, induced DNA damage as manifested by histone H2AX phosphorylation in CD34+ leukemia cells, with greater phosphorylation in cells from responders. Conclusions: The veliparib/topotecan/carboplatin combination warrants further investigation, particularly in patients with aggressive MPNs, CMML, and MPN- or CMML-related acute leukemias.

UR - http://www.scopus.com/inward/record.url?scp=85012878602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012878602&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-1274

DO - 10.1158/1078-0432.CCR-16-1274

M3 - Article

VL - 23

SP - 899

EP - 907

JO - Clinical Cancer Research

T2 - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -